Rocket Lab's Revenue Is Soaring. So Why Is the Stock Sinking?

Rocket Lab’s stock is down ~58% from early-year highs as Neutron’s planned debut slides to early 2027, extending the period before the rocket generates launch revenue at scale. Revenue rose 62% YoY last quarter to $234.1M total, but space-systems revenue ($189.5M) still outpaced launch ($44.6M) and the company remains unprofitable with low gross margins. Despite a $769M trailing revenue base and plans to accelerate growth via the Iridium Communications acquisition, the article flags valuation risk with a P/S of 48, suggesting significant growth is already priced in.

Analysis

The market reaction is mostly about credibility, not lost revenue. A slip to 2027 pushes the core growth narrative further out, which means the stock’s very high sales multiple is vulnerable to compression even if the current quarter remains fine. In the near term, that favors sellers of momentum and higher-quality launch substitutes because customers and investors will re-rate toward proven cadence, not aspirational platform value.

Second-order, the delay weakens the “bundle” thesis: if launch capacity stays constrained, Rocket Lab’s systems business has less ability to lock in payload design wins and cross-sell components at scale. That leaves SpaceX as the dominant benchmark for integrated launch economics, and it also raises the risk that prospective government/commercial customers treat Rocket Lab as a niche supplier rather than a platform company. If Neutron slips again or test milestones stay vague over the next 1-3 months, the downside is more about multiple and financing optics than fundamental revenue.

The contrarian view is that the market may be over-anchoring on one program while underappreciating that systems already generate the bulk of revenue. If management can show accelerating margins in systems and credible Neutron test cadence, the stock could stabilize well before first commercial launch. But absent hard milestones, this remains a patience trade at best, not a “buy the dip” setup; the thesis is falsified by a clear schedule pull-forward, better-than-expected gross margin inflection, or meaningful order conversion tied to Neutron progress.

Key Decisions for Investors

• Short RKLB into any post-news bounce; use a 3-6 month horizon and define risk at the next disclosed Neutron milestone. Reward is continued de-rating toward a more normal sales multiple if the 2027 timing holds.
• Prefer RKLB put spreads over outright puts if implied volatility is elevated; the catalyst is further schedule slippage or a cautious update, while the main risk is a temporary sentiment squeeze on any backlog headline.
• No urgent long IRDM call on the acquisition angle yet; treat IRDM as a watch item until deal terms or integration economics are disclosed. Missing data: purchase price, expected synergy, and whether the transaction is dilutive to Rocket Lab cash burn.
• Set an alert on any Neutron test-flight calendar or management guidance revision. If a credible launch date or hardware milestone is pulled forward, cover shorts quickly because the valuation can re-rate sharply on execution proof.
• If seeking sector exposure, favor proven cash-generative aerospace/defense names over RKLB until launch cadence is demonstrated. The market is likely to reward certainty and punish story-stock optionality over the next 1-3 quarters.